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Abstract 
 
Tau pathology is a defining characteristic of multiple neurodegenerative disorders including 
Alzheimer’s Disease (AD) and Frontotemporal Dementia (FTD) with tau pathology.  There is 
strong evidence from genetics and experimental models to support a central role for tau 
dysfunction in neuronal death, suggesting tau is a promising therapeutic target for AD and 
FTD.  However, the development of tau pathology can precede symptom onset by several 
years, so understanding the earliest molecular events in tauopathy is a priority area of 
research. Induced pluripotent stem cells (iPSC) derived from patients with genetic causes of 
tauopathy provide an opportunity to derive limitless numbers of human neurons with 
physiologically appropriate expression levels of mutated genes for in vitro studies into 
disease mechanisms. This review discusses the progress made to date using this approach 
and highlights some of the challenges and unanswered questions this technology has the 
potential to address. 
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The importance of tau in neurodegeneration 
The accumulation of hyperphosphorylated aggregates of the microtubule associated protein 
tau characterise a range of clinically diverse disorders collectively termed the tauopathies, 
including Alzheimer’s Disease (AD) and frontotemporal dementia (FTD)(1).  A direct link 
between tau dysfunction and neurodegeneration was confirmed by the discovery of 
mutations in the tau gene, MAPT, that cause FTD with tau pathology (2,3).  Further genetic 
evidence linking MAPT to neurodegeneration is provided by the existence of two major 
haplotype blocks at the MAPT locus, H1 and H2.  The H1 haplotype is associated with 
increased susceptibility to several sporadic tauopathies, including progressive supranuclear 
palsy (PSP) and corticobasal degeneration (CBD), as well as Parkinson’s Disease (PD) (4–
6).  Mutations in MAPT do not cause AD, however there are several lines of evidence 
strongly supportive of a crucial role for tau in the AD pathological cascade.  The extent of tau 
pathology is strongly correlated with symptom severity and neuronal cell loss (7).  Further, 
experimental models have demonstrated that tau reduction is neuroprotective against 
amyloid, demonstrating an essential role for tau as a mediator of amyloid toxicity (8,9).  
Therefore, tau is an attractive therapeutic target for a broad range of neurodegenerative 
disorders and understanding the mechanisms linking tau to neurodegeneration is a research 
priority.  A comprehensive review of the role of tau protein in health and disease can be 
found here (1). 
A major limitation in our ability to understand the molecular mechanisms linking tau and 
neurodegeneration has been the availability of experimental models recapitulating key 
features of disease.  For example, it has been difficult to generate rodent models that 
reliably recapitulate tau tangles and neuronal loss pathology, and certain aspects of tau 
biology that are important for neuronal health, notably its alternative splicing, are species-
specific and experimental models do not recapitulate patterns observed in the adult human 
CNS.  It is important to note that tau dysfunction and aggregation begin decades before the 
onset of clinical symptoms, by which time substantial neuronal cell loss has occurred, 
therefore treatment at pre-symptomatic stages is likely to be the most successful therapeutic 
strategy (10).  Experimental models that allow the earliest stages of tauopathy to be 
dissected at the molecular level will be an important addition to the experimental toolkit.  For 
the past 10 years, it has been possible to generate stem cells from terminally differentiated 
cell types, termed induced pluripotent stem cells (iPSC).  As iPSC can be differentiated into 
any cell type of interest, including neurons, this technology can be used to generate limitless 
numbers of human cells, capturing the precise genetic make-up of the donor, making them a 
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powerful tool for the study of disease mechanisms (reviewed in 11,12). Here, I will discuss 
the progress and challenges of using this approach to create in vitro models of tauopathy. 
 
iPSC as models of neurological disease 
Our ability to generate in vitro models of neurological disease was revolutionised by the 
description of methods to reprogram terminally differentiated cells such as fibroblasts to 
pluripotency by the exogenous expression of pluripotency-associated transcription factors 
including (but not limited to) Oct4, Sox2, Klf4 and cMyc (13).  The resulting iPSC are 
indistinguishable from embryonic stem cells across a number of key characteristics, 
including the ability to maintain a stable karyotype, expression of pluripotency genes, and 
their ability to be differentiated into any cell type of interest.  Protocols for the directed 
differentiation into many specific neuronal subtypes exist, thus iPSC can provide a limitless 
supply of human neurons for the study of neuronal development and disease mechanisms 
(14).  By taking the initial primary material from patients with a known genetic cause of 
disease, one can therefore generate “dementia in a dish” models to study the effects of 
these genetic mutations in a disease-relevant cell type and at physiological expression 
levels.  These models have provided the field with an exciting opportunity to gain insight into 
disease mechanisms as well as developing humanised platforms for drug screening.  
 
Modelling tau pathology in iPSC-neurons from AD  
 
Much of what we know about the molecular mechanisms of AD has come from the study of 
rare genetic forms of the disease (familial AD, fAD) caused by mutations in the genes 
encoding the amyloid precursor protein (APP), and presenilin 1 and 2 (PSEN1 and PSEN2) 
which are components of the γ-secretase complex responsible for proteolytic cleavage of 
APP into its smaller fragments (15).  All of these mutations lead to altered processing of 
APP, favouring the production of aggregation-prone Aβ peptides and amyloid plaque 
formation, and ultimately leading to downstream tau pathology.  Many groups have now 
used iPSC-neurons with mutations in these three genes to gain insight into disease 
pathologies and disease mechanisms. 
 
There are now numerous studies using iPSC-neuron models of fAD, which have universally 
demonstrated altered APP processing and the production and secretion of disease-
associated Aβ peptides as a feature of these in vitro models, confirming the effects of fAD 
mutations are replicated faithfully in iPSC-neurons (16–23).  Interestingly, unusual mutations 
such as the APP E693Δ variant resulted in intracellular Aβ accumulation as seen in patients, 
confirming this system can be used to reliably recapitulate specific mutation effects in vitro 
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(18).  Human cortical neurons from individuals with Down Syndrome (who carry an extra 
copy of the APP gene) developed amyloid aggregates positive for the Thioflavin-S analog 
BTA1 (24). These robust read-outs of pathogenic mutations enable translation into medium 
and high-throughput platforms for drug screening, which has been successfully performed in 
this context to reveal modulators of APP processing (17,25). 
 
A key question of iPSC models of fAD is whether they can be used to probe the links 
between amyloid and tau in the context of a human in vitro model.  Elevated tau 
phosphorylation, mislocalisation and increased insolubility of tau has been described in 
numerous fAD iPSC models, confirming disease-associated changes to tau in vitro.  
Interestingly, a number of reports have described elevated tau protein levels in iPSC with 
APP coding or dosage mutations (19,20).  This was apparent at the protein level but not the 
mRNA level, suggesting a previously unrecognised relationship between APP processing 
and tau proteostasis.  iPSC have also been generated from sporadic AD patients (sAD) 
which account for the majority of AD cases.  Elevated Aβ and tau phosphorylation was 
observed in some, but not all, of these neuronal cultures, highlighting the challenges of using 
this system to interrogate sporadic disease due to the inherent variability between different 
patient lines, driven largely by genetic background (18,23,26).  
 
In addition to recapitulating amyloid and tau changes, iPSC-neurons from fAD patients have 
demonstrated a variety of cellular phenotypes including increased susceptibility to oxidative 
stress, abnormal endosomes and altered axonal transport (18,23,27).  Whether any of these 
phenotypes can be rescued by modifying the levels or phosphorylation state of tau remains 
to be determined and will be an important area of future research.  It is also important to 
note that these 2D culture systems have, so far, not generated both amyloid plaques and tau 
tangles within a single in vitro system. 
 
3D models of AD 
In addition to 2D, adherent neuronal cultures, there are several methods available for the 
generation of 3-Dimensional disease models.  Recent reports have harnessed the intrinsic 
ability of stem cells to self-organise in non-adherent conditions to form cerebral organoids, 
which contain a diversity of neuronal cell types representative of different brain regions and 
display rudimentary architecture such as neuronal layering (28). 
 
The cellular diversity and architecture offered by cerebral organoids confers several 
advantages over 2D adherent cultures.  It should be noted, however that gene expression 
studies show cerebral organoids to closely resemble fetal brain, so although a powerful tool 
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for the study of development, to what extent organoids will recapitulate the pathophysiology 
of later-onset diseases remains to be determined (29).  Raja and colleagues generated 
cerebral organoids from fAD iPSC with APP duplications or PSEN1 M146I and A264E 
mutations (30).  These organoids showed a time-dependent increase in Aβ40 and Aβ42 
when compare to controls, and amyloid accumulations were visible on tissue sections from 
these organoids.  Further, this was accompanied by an increase in phosphorylated tau at 
T181 and S396 that was only apparent after 90 days in culture. Together these data support 
the utility of 3D organoids for AD research. 
 
A separate study used human neuronal progenitor cells overexpressing APP and PSEN1 
with fAD mutations to drive the formation of AD pathologies (31,32). These neuronal 
progenitor cells produce a 9 fold increase in Aβ40 and a 17 fold increase in Aβ42 after 6 
weeks of differentiation in comparison to wild type cells.  3D neuronal cultures were 
generated from these lines by embedding in the 3D support matrix Matrigel, accelerating the 
accumulation of insoluble Aβ monomers and oligomers together with sarkosyl-insoluble, 
hyperphosphorylated, filamentous tau.  It remains to be determined whether both amyloid 
and tau tangle pathologies can be recapitulated in a single cell culture system in the 
absence of overexpression of mutant fAD genes. 
  
 
Chimeric models of AD 
A major challenge in the field of AD has been the production of rodent models that 
recapitulate the hallmark plaque and tangle pathologies of AD, together with neuronal loss 
(33,34).  A recent study generated chimeric models by transplanting human iPSC-derived 
neurons into either immunodeficient wild-type mice or immunodeficient APPPS1 mice, which 
contain human transgenes expressing APPSwe and PSEN1 L166P, and develop age-
dependent amyloid deposition (35).  In wt mice the human neurons integrated without signs 
of degeneration, however in the AD model there was a progressive degeneration of the 
transplanted human neurons from 6 months onwards (36).  Neighbouring mouse neurons 
remained unaffected, demonstrating selective vulnerability of human neurons.  Interestingly, 
abnormal tau was detected in the human neurons by immunohistochemistry with MC1, an 
antibody that detects conformational alterations of tau associated with early stages of 
disease.  However, neuronal death occurred in the absence of tangle formation, supporting 
the idea of dissociation between tau tangle formation and cell death. 
 
Modelling tau mutations in iPSC neurons 
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The discovery of coding and splice-site mutations in MAPT that are causative of FTD 
confirmed the link between tau dysfunction and neurodegeneration (2,3).  To date, over 40 
MAPT mutations have been described (http://www.alzforum.org/mutations), with the majority 
located in exons 9-12 of MAPT which code for the microtubule binding repeats.  The 
generation of experimental models featuring MAPT mutations provide insight into the 
mechanisms linking tau and neurodegeneration in FTD, but can be more broadly 
extrapolated to AD.  As discussed below, several groups have used iPSC to successfully 
model MAPT mutations although there are several challenges associated with this 
approach, given that several aspects of tau biology relevant to disease are also 
developmentally regulated. 
 
Tau splicing in iPSC-neurons 
The alternative splicing of exons 2, 3 and 10 of the MAPT gene leads to the generation of six 
protein isoforms of tau in the adult human central nervous system (CNS).  Exons 2 and 3 
code for the N-terminal repeats of tau, and exon 10 codes for an extra microtubule binding 
repeat, and tau isoforms are characterised as either 3R (3 repeats) or 4R (4 repeats) 
accordingly (37,38).  Thus, the six isoforms of tau are 0N3R, 0N4R, 1N3R, 1N4R, 2N3R and 
2N4R.  The levels of these are tightly controlled and appear to be critical for neuronal health: 
in normal circumstances the levels of 3R and 4R are approximately equal, but mutations in 
MAPT which disrupt this ratio (generally favouring an increase in exon 10 inclusion) are 
sufficient to cause FTD (39).  A similar increase in 4R tau isoforms is also observed in the 
sporadic tauopathies PSP and CBD (40,41). 
 
How an overproduction of specific tau isoforms can lead to neurodegeneration is an 
intriguing and unanswered question.  A big challenge in this area has been the lack of 
appropriate experimental models to study disrupted tau splicing: it has been difficult to 
produce in vitro and in vivo models that recapitulate the complex nature of tau splicing seen 
in the adult human CNS.  A human, neuronal model that correctly splices tau would be an 
important advance in this regard.  
Human primary neurons have been shown to express and splice tau in a manner resembling 
the adult human CNS, however these have not been widely adopted due to the 
inavailability/ethical issues of using aborted fetal material (42).  iPSC therefore offer an 
attractive opportunity to generate human neurons in vitro which would be predicted to 
recapitulate tau expression as seen the adult CNS.  However, tau splicing is also subject to 
developmental regulation: the smallest (0N3R) is predominantly expressed during fetal 
stages with a post-natal switch to six tau isoforms (37).  Several groups have now reported 
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that iPSC-neurons express predominantly the fetal tau isoform at early culture time-points, 
with other isoforms only expressed in substantial amounts after extended in vitro culture 
times (43–45). This is perhaps unsurprising in the context of genome-wide expression data 
demonstrating that iPSC-neurons strongly resemble fetal human brain (46).  However, 
several MAPT mutations are located within alternatively spliced exons so this is an important 
point to consider when using iPSC-neurons for disease modelling. 
 
Several protocols have now established an accelerated differentiation of iPSC into neurons, 
and for the direct conversion (trans-differentiation) of fibroblasts into neurons, which may 
promote retention of biological signatures of aging (47–49).  It is interesting to speculate 
whether these accelerated neuronal differentiation paradigms will also accelerate the 
acquisition of mature tau isoforms.  The splicing of MAPT can also be artificially controlled to 
favour 3R or 4R isoform expression using trans-splicing, resulting in altered axonal transport 
of cargo including APP (27). 
 
Importantly, many groups have now shown that exonic and intronic MAPT mutations 
associated with altered tau splicing are able to disrupt tau splicing in vitro.  iPSC-neurons 
with the N279K, 10+16, and 10+14 MAPT mutations all lead to an overproduction of 4R tau 
isoforms as seen in patients (43,45,50).   
 
Neuronal phenotypes in MAPT mutation neurons 
In spite of the developmental regulation of tau, iPSC models have shown multiple 
phenotypes relevant to FTD pathogenesis.  An increase in insoluble tau was detected in 
neurons with the 10+14 intronic mutation, and the A152T and R406W coding variants in tau 
(51,52).  The best-characterised function of tau is its role as a microtubule associated 
protein, prompting several groups to examine whether intracellular trafficking and axonal 
transport could be disrupted in iPSC-neurons with MAPT mutations.  Altered splicing and 
coding mutations in tau resulted in altered vesicle trafficking and an altered distribution of 
mitochondria within neurons (45,50).  Mitochondrial dysfunction and reduced ATP 
production was observed in neurons with the 10+16 mutation, which could be related to 
disrupted mitochondrial transport (53). Dysregulated calcium signalling and an upregulation 
in markers of cell stress (including mitochondrial stress, altered endosome/lysosome 
composition, increased markers of stress granules) confirm the ability of tau mutations to 
induce neuronal dysfunction in vitro (50,51,54). Interestingly, neuronal connectivity may be 
disrupted by tau mutations: both splice-site and coding mutations in MAPT lead to an 
accelerated acquisition of electrical maturity in vitro (45).  
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Tau seeding and spread in iPSC-neurons 
In AD, tau pathology spreads between connected regions of the brain in a temporal and 
spatially predictable manner that correlates with symptom severity and the extent of 
neuronal loss.  An area of intense research is now focussed on understanding the trans-
synpatic spread of tau and the ability of pathological tau species to seed aggregation in 
recipient neurons, and human iPSC-neurons will be a powerful tool in these investigations. 
Truncated tau species lacking the C-terminus of the protein is readily detectable in 
conditioned media from iPSC-neurons (55), and a recent study showed tau release from 
iPSC-neurons is activity dependent (56).  Pre-formed tau aggregates were able to induce 
tau aggregation and hyperphosphorylation in iPSC-neurons transduced with the pro-
aggregation P301L mutant, in an assay that has been successfully scaled into 384-well 
format that can be used to screen for inhibitors of tau aggregation(57,58).  
 
Conclusion 
Since the first description of iPSC 10 years ago, numerous groups have used this 
technology to generate in vitro models for AD and FTD.  These have demonstrated the 
power of this approach to create “disease in a dish” models that capture key aspects of AD 
and FTD pathology, including altered APP processing, tau splicing, phosphorylation and 
aggregation.  These models have provided insight into novel disease mechanisms in 
addition to providing humanised platforms for drug-screening.  This review has focussed on 
iPSC models from patients with a known genetic cause of tauopathy.  The advent of 
genome-wide association studies (GWAS) has identified many genetic risk variants, 
investigation of the molecular mechanisms linking these to disease pathology will be an 
exciting area of future research.  There are several challenges to overcome in the use of 
iPSC as models for adult-onset neurodegenerative disease, including the developmental 
maturity of the resulting neurons, reductionist approach of studying isolated cell types, and 
the variability between iPSC from different donors.  New protocols for accelerated 
differentiation, co-culture of multiple cell types, and generation of isogenic lines using 
CRISPR will enable the generation of robust models with greater physiological relevance.  In 
this rapidly moving field, it is clear that iPSC will continue to contribute greatly to our 
enhanced understanding of tauopathy.  
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